Objective: The chimeric anti-tumor necrosis factor-alpha antibody infliximab is known to induce antibodies-to-infliximab (ATI) in some treated patients. Immunogenicity in murine variable domains is expected; however, constant domains of its human heavy gamma1 chain may also be implicated as it expresses G1m1 and G1m17 allotypes. This allelic form may be immunogenic in patients that are homozygous for the G1m3 allotype commonly expressed in Caucasoid populations.
Methods: As G1m allotypic divergence may explain the presence of ATI or may influence their concentration, a genotyping method was developed and validated to determine antithetical (i.e. mutually exclusive) G1m3 and G1m17 allotypes (amino acid 120 of CH1 according to the international ImMunoGeneTics information system unique numbering) at the IGHG1 gene level (CH1 359g/a nucleotide polymorphism). Two hundred forty-five blood donors and 118 previously described patients suffering from Crohn's disease, treated with infliximab, and having developed ATI in 73 of them, were genotyped.
Results: The IGHG1 CH1 359g/a polymorphism does not depart from the Hardy-Weinberg equilibrium in the control population, and allele frequencies were similar in controls and patients. No association was found between the patient G1m allotypes and the presence of ATI or their concentration. It remains possible that anti-Gm1 antibodies are not well detected by the enzyme-linked immunosorbent assays used for ATI detection and/or that the G1m allotypes are minor antigens on IgG1.
Conclusion: The IGHG1 polymorphism does not seem to play a major role in the induction of ATI. Further analyses will be required to determine whether it is also the case for humanized or fully human antibodies bearing the same G1m allotypes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/FPC.0b013e32832a06bf | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sequence variants influencing the regulation of serum IgG subclass levels.
Nat Commun
September 2024
deCODE genetics/Amgen Inc., Reykjavik, Iceland.
Article Synopsis
- Immunoglobulin G (IgG) is the primary type of antibody in human blood and exists in four subclasses (IgG1 to IgG4), which are influenced by specific genes.
- A genome-wide association study involving 4,334 adults and 4,571 children identified ten new variants and confirmed four known variants linked to IgG subclass levels, affecting conditions like asthma and autoimmune diseases.
- Significant links were found between certain genetic allotypes and specific IgG subclasses, with notable findings showing that lower IgG4 levels can both protect against childhood asthma and increase the risk of inflammatory bowel disease.
Immunoglobulin G genetic variation can confound assessment of antibody levels via altered binding to detection reagents.
Clin Transl Immunology
February 2024
Department of Microbiology and Immunology The Peter Doherty Institute for Infection and Immunity, University of Melbourne Melbourne VIC Australia.
Article Synopsis
- The study investigates how variations in immunoglobulin (Ig) allotypes, particularly of IgG1, can affect the accuracy of antibody detection in diverse genetic populations, focusing on two key haplotypes (G1m-1,3 and G1m1,17).
- Four commercial monoclonal antibodies were tested for their ability to recognize these haplotypes using assays, revealing that one antibody (4E3) showed a strong preference for binding to the G1m1,17 variant.
- The findings suggest that this bias in detection affects the interpretation of antibody responses in vaccinated and convalescent individuals, highlighting the importance of validating antibody clones against different Ig variants to improve accuracy in clinical assessments.
A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcγR Complex Formation After Vaccination.
Front Immunol
May 2022
Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, United States.
Fc-mediated immune functions have been correlated with protection in the RV144 HIV vaccine trial and are important for immunity to a range of pathogens. IgG antibodies (Abs) that form complexes with Fc receptors (FcRs) on innate immune cells can activate Fc-mediated immune functions. Genetic variation in both IgGs and FcRs have the capacity to alter IgG-FcR complex formation changes in binding affinity and concentration.
View Article and Find Full Text PDFNovel approach to monitor intravenous immunoglobulin pharmacokinetics in humans using polymorphic determinants in IgG1 constant domains.
Eur J Immunol
April 2022
Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands.
Article Synopsis
- Researchers found a new way to measure a treatment called IVIg, which helps some sick patients, by using special tests that look for specific types of antibodies in their blood.
- This method was able to detect very small amounts of IVIg in patients, especially those with a condition called Guillain-Barré syndrome.
- The tests could show differences in how the body clears out the treatment compared to regular antibodies, which means they can help doctors understand how well IVIg is working for different patients.
The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
Front Immunol
March 2021
EA7501 Groupe Innovation et Ciblage Cellulaire, Equipe Fc Récepteurs, Anticorps et MicroEnvironnement, Université de Tours, Tours, France.
The hinge region of immunoglobulin G (IgG) is involved in C1q and FcγRIIIA-expressing natural killer (NK) cell recruitment. Both heavy chains (HCs) of the hinge region can be cleaved sequentially by several proteases of the tumor/inflammatory/infectious microenvironment, including matrix metalloproteinase 12 (MMP12), or immunoglobulin-degrading enzyme from (IdeS), impairing Fc-mediated functions. The cleavage of therapeutic monoclonal antibodies (TmAbs), which are based on a human IgG1, IgG2 or IgG4 structure, has been poorly investigated, although it may represent an escape mechanism to these treatments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!